NKTR

Business Context and Reporting Period

Company: Nektar Therapeutics
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2004
Business Overview: Nektar is a drug delivery technology company focused on three platforms: Advanced PEGylation, Pulmonary Technology, and Supercritical Fluid (SCF) Technology. The company operates primarily through collaborations with pharmaceutical partners (e.g., Pfizer, Roche, Amgen) to develop and commercialize products, while also pursuing a smaller portfolio of proprietary products. Key partnered products include Exubera (inhaled insulin) and Macugen (eye disease treatment).

Key Financial Metrics

Liquidity: The company held approximately $418.7 million in cash and short-term investments as of December 31, 2004. Management forecasts sufficient cash to meet net operating expense requirements for at least the next two years.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 8% to $114.3 million, driven by a 13% increase in contract research revenue (primarily from Pfizer's Exubera collaboration) and a 48% increase in product sales in 2003, though product sales declined 8% in 2004 due to lower demand for Neulasta, Somavert, and PEGASYS.
• Increased Net Loss: Net loss widened to $101.9 million from $65.9 million in 2003. This was driven by higher R&D spending ($133.5 million vs. $122.1 million), a $9.3 million loss on debt extinguishment, and increased interest expense ($25.7 million vs. $19.3 million) due to "make-whole" payments on convertible notes.
• Debt Reduction: Convertible subordinated notes decreased significantly from $360.0 million to $173.9 million following the conversion of $133.3 million of 3% notes into common stock in March 2004 and other private exchanges.
• Manufacturing Issues: Production problems in Q2 and Q3 2004 caused a temporary shutdown of Advanced PEGylation manufacturing, reducing product gross margin from 46% in 2003 to 21% in 2004.

Guidance, Outlook, Risks, and Unusual Items

• Exubera Status: In March 2005 (post-period), Pfizer and Sanofi-Aventis announced the FDA accepted the New Drug Application (NDA) for Exubera. The company remains heavily dependent on this product; Pfizer represented 61% of 2004 revenue.
• Internal Control Material Weakness: Management and auditors identified a material weakness in internal controls over financial reporting due to insufficient review of accounting policies and disclosures. This resulted in the restatement of 2002 and 2003 financial statements (reclassifying expenses between R&D, G&A, and interest).
• Accounting Changes: The company must adopt FAS 123R (Stock-Based Compensation) in July 2005, which will materially increase compensation expense and negatively impact reported earnings.
• Legal Proceedings: A securities class action lawsuit was filed in September 2004 alleging false statements regarding Exubera. The outcome is uncertain but could have a material adverse effect.
• Debt Maturity: All outstanding convertible subordinated debt ($173.9 million) matures in 2007. The company does not expect to generate sufficient cash flow to repay this obligation and may need to raise additional capital or restructure debt.

Investor Verification Checklist

• Exubera Approval Timeline: Verify the status of the FDA and EMEA approval for Exubera, as the company's financial viability is heavily tied to this single product launch.
• Debt Refinancing Strategy: Confirm the company's plan to address the $173.9 million debt maturing in 2007, given the lack of current profitability.
• Internal Control Remediation: Review subsequent filings to ensure the material weakness in financial reporting controls has been effectively remediated.
• Manufacturing Capacity: Assess whether the manufacturing issues that impacted 2004 gross margins have been fully resolved and if capacity is sufficient for potential commercial launch.
• Impact of FAS 123R: Monitor the adoption of new stock-based compensation accounting rules in 2005 and its impact on future net loss figures.